Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Molecular Response and SuperGen enter translational oncology agreement

Aug. 2, 2011

Novel c-Akt inhibitors synthesized at ArQule

Aug. 2, 2011

Merck KGaA presents novel sphingosine kinase 1 inhibitors

Aug. 2, 2011

Polaris doses first patient in pivotal phase III ADI-PEG 20 trial

Aug. 1, 2011

ArQule presents novel inhibitors of cyclin-dependent kinase 7 and CaMK-II

Aug. 1, 2011

FDA awards orphan drug status to Diffusion Pharmaceuticals' TSC

July 29, 2011

Yaupon Therapeutics files NDA for mechlorethamine gel

July 29, 2011

Enrollment begins in randomized phase II trial of NGR-hTNF in ovarian cancer

July 29, 2011

ArQule prepares novel protein kinase inhibitors

July 29, 2011

CNIO patents novel protein kinase pim inhibitors

July 29, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...